Skip to main content

Journal Club - March 3, 2022

APAF-CRT Mortality Trial

Jason Gencher presented the APAF-CRT Mortality Trial which was an international, open-label, blinded outcome trial of patients with severely symptomatic permanent atrial fibrillation for greater than 6 months, a narrow QRS (≤110 ms) and at least one HF hospitalization in the previous year. The patients were randomized to either ablation plus CRT or to pharmacological rate control. Patients were followed for a median of 29 months looking at a primary endpoint of all-cause mortality. The trial was published in the European Heart Journal in December and presented at ESC this past summer.

CCI is an inclusive centre with multidisciplinary membership for all cardiovascular investigators in BC